Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InhaleRx Limited ( (AU:NX1) ) just unveiled an announcement.
Nexalis Therapeutics Ltd, previously trading as InhaleRx Limited, has confirmed its corporate details in its latest annual report, including its Melbourne head office, principal place of business and updated branding. The company remains listed on the ASX under code NX1, with a refreshed board and governance framework that underscores its ongoing presence and compliance in the Australian biotech and therapeutics market.
The report outlines the current non-executive leadership team, company secretary, external auditor and share registry provider, signalling operational stability and adherence to regulatory standards. This updated corporate structure and rebranding effort suggests Nexalis is consolidating its identity and governance as it advances its activities in the therapeutics industry, providing stakeholders with clarity on its organisational setup and market listing status.
The most recent analyst rating on (AU:NX1) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on InhaleRx Limited stock, see the AU:NX1 Stock Forecast page.
More about InhaleRx Limited
Nexalis Therapeutics Ltd, formerly known as InhaleRx Limited, is an Australian biopharmaceutical company listed on the Australian Securities Exchange under the ticker NX1. The company operates from Melbourne and focuses on therapeutic development, positioning itself within the broader life sciences and healthcare sector.
Average Trading Volume: 242,511
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.07M
Find detailed analytics on NX1 stock on TipRanks’ Stock Analysis page.